{
    "clinical_study": {
        "@rank": "18355", 
        "arm_group": [
            {
                "arm_group_label": "1% MIM-D3", 
                "arm_group_type": "Active Comparator", 
                "description": "1% MIM-D3 Ophthalmic Solution"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution\n      compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye."
        }, 
        "brief_title": "A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dry Eye Syndromes", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be at least 18 years of age\n\n          -  Provided written informed consent\n\n          -  Have a reported history of dry eye\n\n          -  Have a history of use or desire to use eye drops for dry eye\n\n        Exclusion Criteria:\n\n          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or\n             active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been\n             diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or\n             conjunctiva, within the last 12 months\n\n          -  Have any planned ocular and/or lid surgeries over the study period\n\n          -  Have corrected visual acuity greater than or equal to +0.7 as assessed by Early\n             Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1\n\n          -  Have an uncontrolled systemic disease\n\n          -  Be a woman who is pregnant, nursing or planning a pregnancy\n\n          -  Be a woman of childbearing potential who is not using an acceptable means of birth\n             control; acceptable methods of contraception include: hormonal - oral, implantable,\n             injectable, or transdermal contraceptives; mechanical - spermicide in conjunction\n             with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of\n             partner. For non-sexually active females, abstinence may be regarded as an adequate\n             method of birth control; however, if the subject becomes sexually active during the\n             study, she must agree to use adequate birth control as defined above for the\n             remainder of the study\n\n          -  Have a known allergy and/or sensitivity to the test article or its components\n\n          -  Have a condition or be in a situation which the investigator feels may put the\n             subject at significant risk, may confound the study results, or may interfere\n             significantly with the subject's participation in the study\n\n          -  Be currently enrolled in an investigational drug or device study or have used an\n             investigational drug or device within 45 days of Visit 1\n\n          -  Be unable or unwilling to follow instructions, including participation in all study\n             assessments and visits"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960010", 
            "org_study_id": "MIM-725"
        }, 
        "intervention": [
            {
                "arm_group_label": "1% MIM-D3", 
                "description": "1% MIM-D3 dosed BID", 
                "intervention_name": "MIM-D3 Ophthalmic Solution", 
                "intervention_type": "Drug", 
                "other_name": "1% MIM-D3"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Vehicle dosed BID", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug", 
                "other_name": "Placebo Ophthalmic Solution"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Waterbury", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06708"
                    }, 
                    "name": "MIM-725 Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lewiston", 
                        "country": "United States", 
                        "state": "Maine", 
                        "zip": "04240"
                    }, 
                    "name": "MIM-725 Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Andover", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01810"
                    }, 
                    "name": "MIM-725 Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quincy", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02169"
                    }, 
                    "name": "MIM-725 Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38119"
                    }, 
                    "name": "MIM-725 Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye", 
        "other_outcome": [
            {
                "description": "Fluorescein Staining, (pre and post-CAESM; by individual region: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum, and total), by both grade and clearance of staining;", 
                "measure": "Fluorescein staining (Ora CalibraTM Scale)", 
                "safety_issue": "No", 
                "time_frame": "Day 15, 29 and 57"
            }, 
            {
                "description": "Lissamine green staining  (pre and post-CAESM; regions: central, superior, inferior, temporal, nasal, corneal sum, conjunctival sum, and total)", 
                "measure": "Lissamine green staining (Ora CalibraTM Scale,)", 
                "safety_issue": "No", 
                "time_frame": "Day 15, 29 and 57"
            }, 
            {
                "measure": "Subject diary individual symptoms", 
                "safety_issue": "No", 
                "time_frame": "28-day and 56-day treatment periods"
            }, 
            {
                "description": "Tear film break-up time (pre and post-CAESM);", 
                "measure": "Tear film break-up time", 
                "safety_issue": "No", 
                "time_frame": "Day 15, 29 and 57"
            }
        ], 
        "overall_official": {
            "affiliation": "Mimetogen Pharmaceuticals USA, Inc.", 
            "last_name": "Garth Cumberlidge, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Corneal Fluorescein Staining", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "Patient-derived, daily dryness symptoms for the 28 day time period will be be averaged to obtain a dryness score for the entire 28-day period.  Average dryness scores over the 28-day treatment period will be compared between 1% MIM-D3 and placebo using t-tests.", 
                "measure": "Ocular Dryness", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960010"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Total Ocular Fluorescein Staining", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "description": "Patient-derived daily diary ocular discomfort symptoms for the 28 day time period will be averaged to obtain an ocular discomfort score for the entire 28-day period. Average ocular discomfort scores over the 28-day treatment period will be compared between 1% MIM-D3 and placebo using t-tests.", 
                "measure": "Ocular Discomfort", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "source": "Mimetogen Pharmaceuticals USA, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mimetogen Pharmaceuticals USA, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}